The stock is up by 20 per cent from its 52-week low of Rs 911.75 per share.

The stock gave multibagger returns of 449 per cent from its 52-week low of Rs 5.82 per share.

The company has been actively expanding its product pipeline, with over 70 commercialized products and a healthy pipeline of 100+ approved products.

The stock’s 52-week high is Rs 1,678.60 per share while its 52-week low is Rs 489.20 per share.

From Rs 34.51 per share (52-week low) to Rs 38.29 per share, the stock is up by 11 per cent.

Zydus Lifesciences Limited, a prominent player in the Indian pharmaceutical sector, is currently trading at a stock price of Rs 900 with a market capitalization of over Rs 90,000 crores.

Alkem Laboratories Ltd. is a prominent Indian pharmaceutical company known for its high-quality medicines over the past 50 years.

The stock gave multibagger returns of 475 per cent from its 52-week low of Rs 5.82 per share.

The company has a market cap of over Rs 300 crore and the stock is up by 24.1 per cent from its 52-week low of Rs 50.42 per share.

Pharma Company Expands Injectable Portfolio with New Launch Targeting U.S. Hospital Market

The company has maintained a final dividend of Rs 117 per equity share, subject to shareholder approval.

The stock gave multibagger returns of 467 per cent from its 52-week low of Rs 5.82 per share.

FDA-Approved & Ready! This Pharma Giant Targets a USD 113 Million Market!

Revenue grew by 9 per cent YoY to Rs 2,245.4 crore, up from Rs 2,052.9 crore in the corresponding quarter last year.

The company reported a net income of Rs 8,552 crore, marking a 39.5 per cent YoY growth. Total sales increased 10.6 per cent YoY to Rs 56,186 crore from Rs 50,799 crore in Q3 FY24

From Rs 43.42 per share (52-week low) to Rs 48.55 per share, the stock is up by 11.8 per cent. 

The Board of Directors approved the issuance of commercial papers worth Rs 570 crore on a private placement basis

From Rs 43.35 per share (52-week low) to Rs 51.25 per share, the stock is up by 18.2 per cent.

From Rs 43.42 per share (52-week low) to Rs 51.30 per share, the stock is up by 18.15 per cent.

FDA Nod for Key Diabetes Treatment Boosts Market Confidence and Stock Performance

A key injectable biosimilar gets the green light from Japan, driving a 4.5 per cent surge in stock price.

Under the agreement, Akums will receive an upfront payment of EUR 100 million (Rs 880 crore) to fund product development and secure European regulatory approvals for its oral liquid manufacturing facility.

The shares of the company have an ROE of 25 per cent and an ROCE of 32 per cent.

The facility in question, Unit-V, is an active pharmaceutical ingredient (API) manufacturing site operated by Apitoria Pharma Private Ltd, a wholly owned subsidiary of Aurobindo Pharma, located in Pashamylaram Village, Telangana.

From Rs 43.42 per share (52-week low) to Rs 54.90 per share, the stock is up by 26.40 per cent.

Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) significantly increased their holdings in Shilpa Medicare during Q2 of FY25.

The stock gave multibagger returns of 200 per cent in 1 year, 850 per cent in 3 years and a whopping 3,000 per cent in 5 years.

With the USFDA's green light, the Indian pharmaceutical company is poised to expand its product portfolio and strengthen its global presence

Indian Pharma company breaks into European Market with High-Potential Product, Promising New Revenue Streams

The stock gave multibagger returns of 250 per cent in 1 year, 720 per cent in 3 years and a whopping 2,700 per cent in 5 years.

The stock is up by 85 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of 1,895 per cent in 5 years.

The stock is up by 75 per cent from its 52-week low of Rs 270.05 per share and gave multibagger returns of over 1,800 per cent in 5 years.

The company has a market cap of Rs 76 crore and as of September 27, 2024, the stock is trading at Rs 65 per share on NSE.  

From Rs 38.05 to Rs 187.25 per share, the stock gave multibagger returns of 393 per cent in 3 years.

From Rs 35.03 per share (52-week low) to Rs 60.09 per share, the stock is up by 71.5 per cent and gave multibagger returns of 110 per cent in 2 years.

From Rs 33.30 per share (52-week low) to Rs 63.79 per share, the stock is up by 91.6 per cent and gave multibagger returns of 156 per cent in 2 years.

The company has a market cap of Rs 51.55 crore and stock is up by 66 per cent from its 52-week low of Rs 78 per share.

The stock gave multibagger returns of 1,600 per cent in 3 years and a whopping 8,675 per cent in 5 years.

The company's foray into electrolyte manufacturing complements the government's Make in India initiative.

The stock has given 312 per cent return in 3 years!

Vineet Laboratories Ltd experienced a substantial upswing, hitting the upper circuit at Rs. 68.01, driven by an impressive 17.89 times surge in trading volume. The trading floor buzzed with activity as 1,87,011 units changed hands during this dynamic session.

FII stake increase: Foreign Institutional Investors (FIIs) have increased their stake in Lincoln Pharma from 0.63 per cent in September 2022 to 2.59 per cent in September 2023.

Promoter holding increase: The promoter holding in Lincoln Pharma has also increased from 44.09 per cent in September 2022 to 50.53 per cent in September 2023.

Overall, Trident Lifeline Limited's Q1FY24 financial performance demonstrates its strong market position and ability to capitalize on growth opportunities in the pharmaceutical industry.

On Monday, shares of the company surged by 0.56 per cent to trade at Rs 1,041.25.

This drug had estimated annual sales of USD 262 million in the US.

Shares of the company saw a spurt in volume by more than 2.67 times on BSE.

As the season of financial results is on the company has reported numbers; stock surged by 4.25 per cent today. 

The stock has returned 71.50 per cent year to date and in just one year, it has generated multibagger gains of 224.16 per cent.

The only sector which was least affected today was the BSE Healthcare Index, which plunged 1.18 per cent to Rs 23,493.96, despite a sharp decline in the domestic market.

Glenmark Pharmaceuticals Ltd is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses

Shares of the company surged more than 1.80 per cent.

This pharma company stock went 8 per cent high, do you own it?                                                                                                                                                                                                       With its shares up 8 per cent, the Indian multinational pharmaceutical company posted a net profit of Rs 130 crore in the second quarter, while its turnover increased to Rs 4,145 crore.

Shares of the company surged 7 per cent on the day. 

This company is Saurabh Mukherjee's favourite Pharma stock

The shares of Medicamen Biotech are currently buzzing among the investors after soaring 20 per cent on Wednesday amid strong buying interest.

As the stock is trading near its all-time high, it is above all the short and long-term moving averages. This setup is indicating a clear uptrend in the picture of the stock.